Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials

Large trials have shown that sodium glucose co-transporter-2 (SGLT2) inhibitors reduce the risk of adverse kidney and cardiovascular outcomes in patients with heart failure or chronic kidney disease, or with type 2 diabetes and high risk of atherosclerotic cardiovascular disease. None of the trials...

Celý popis

Uložené v:
Podrobná bibliografia
Vydané v:The Lancet (British edition) Ročník 400; číslo 10365; s. 1788 - 1801
Hlavní autori: Baigent, Colin, Emberson, JonathanR, Haynes, Richard, Herrington, William G., Judge, Parminder, Landray, Martin J., Mayne, Kaitlin J., Ng, Sarah Y.A., Preiss, David, Roddick, Alistair J., Staplin, Natalie, Zhu, Doreen, Anker, Stefan D., Bhatt, Deepak L., Brueckmann, Martina, Butler, Javed, Cherney, David Z.I., Green, Jennifer B., Hauske, Sibylle J., Heerspink, Hiddo J.L., Inzucchi, Silvio E., Jardine, Meg J., Liu, Chih-Chin, Mahaffey, Kenneth W., McCausland, Finnian R., McGuire, Darren K., McMurray, John J.V., Neal, Bruce, Neuen, Brendon L., Packer, Milton, Perkovic, Vlado, Sabatine, Marc S., Solomon, Scott D., Vaduganathan, Muthiah, Wanner, Christoph, Wheeler, David C., Wiviott, Stephen D., Zannad, Faiez
Médium: Journal Article
Jazyk:English
Vydavateľské údaje: England Elsevier Ltd 19.11.2022
Elsevier Limited
Predmet:
ISSN:0140-6736, 1474-547X, 1474-547X
On-line prístup:Získať plný text
Tagy: Pridať tag
Žiadne tagy, Buďte prvý, kto otaguje tento záznam!
Buďte prvý, kto okomentuje tento záznam!
Najprv sa musíte prihlásiť.